Journal
CANCER SCIENCE
Volume 99, Issue 11, Pages 2274-2279Publisher
WILEY
DOI: 10.1111/j.1349-7006.2008.00937.x
Keywords
-
Categories
Funding
- Major State Basic Research Plan of China [2006CB910100]
- Natural Science Foundation of Beijing [05G294]
- Natural Science Foundation of Beijing and Science and Technology Commission of Beijing [Y020400 2040111]
Ask authors/readers for more resources
A novel centrosome protein, TCC52, was identified as a cancer-testis (CT) antigen. The TCC52 gene was tissue-restricted in normal tissues but highly expressed in lung cancer tissues and some cancer cell lines. Immunoglobulin G antibody specific to TCC52 was detected in serum samples from patients with prostate cancer (59.4%, 69/116), cholangiocarcinoma (17.6%, 6/34), laryngeal cancer (8%, 8/100) and lung cancer (5.6%, 4/71) in patients, rather than from healthy donors. Based on its restricted expression pattern and immunogenicity in some types of tumor, TCC52, as a novel CT antigen, would be a promising candidate for cancer immunotherapy. (Cancer Sci 2008; 99: 2274-2279).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
